Molecular Therapies for Inherited Retinal Diseases
Following the implementation of next-generation sequencing technologies (e.g., exome and genome sequencing) in molecular diagnostics, the majority of genetic defects underlying inherited retinal disease (IRD) can readily be identified. In parallel, opportunities to counteract the molecular consequen...
Saved in:
HerausgeberIn: | |
---|---|
Sonstige: | |
Year of Publication: | 2020 |
Language: | English |
Physical Description: | 1 electronic resource (262 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993600242604498 |
---|---|
ctrlnum |
(CKB)5400000000042749 (oapen)https://directory.doabooks.org/handle/20.500.12854/69174 (EXLCZ)995400000000042749 |
collection |
bib_alma |
record_format |
marc |
spelling |
Collin, Rob W.J. edt Molecular Therapies for Inherited Retinal Diseases Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020 1 electronic resource (262 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Following the implementation of next-generation sequencing technologies (e.g., exome and genome sequencing) in molecular diagnostics, the majority of genetic defects underlying inherited retinal disease (IRD) can readily be identified. In parallel, opportunities to counteract the molecular consequences of these defects are rapidly emerging, providing hope for personalized medicine. ‘Classical’ gene augmentation therapy has been under study for several genetic subtypes of IRD and can be considered a safe and sometimes effective therapeutic strategy. The recent market approval of the first retinal gene augmentation therapy product (LuxturnaTM, for individuals with bi-allelic RPE65 mutations) by the FDA has not only demonstrated the potential of this specific approach, but also opened avenues for the development of other strategies. However, every gene—or even every mutation—may need a tailor-made therapeutic approach, in order to obtain the most efficacious strategy with minimal risks associated. In addition to gene augmentation therapy, other subtypes of molecular therapy are currently being designed and/or implemented, including splice modulation, DNA or RNA editing, optogenetics and pharmacological modulation. In addition, the development of proper delivery vectors has gained strong attention, and should not be overlooked when designing and testing a novel therapeutic approach. In this Special Issue, we aim to describe the current state of the art of molecular therapeutics for IRD, and discuss existing and novel therapeutic strategies, from idea to implementation, and from bench to bedside. English Research & information: general bicssc Biology, life sciences bicssc induced pluripotent stem cell (iPSC) clustered regularly interspaced short palindromic repeats (CRISPR) homology-directed repair (HDR) Enhanced S-Cone Syndrome (ESCS) NR2E3 AAV retina gene therapy dual AAV gold nanoparticles DNA-wrapped gold nanoparticles ARPE-19 cells retinal pigment epithelium clathrin-coated vesicles endosomal trafficking retinitis pigmentosa autosomal dominant G56R putative dominant negative effect gapmer antisense oligonucleotides allele-specific knockdown Leber congenital amaurosis and allied retinal ciliopathies CEP290 Flanders founder c.4723A > T nonsense mutation Cilia elongation spontaneous nonsense correction AON-mediated exon skipping microRNA photoreceptors rods cones bipolar cells Müller glia retinal inherited disorders retinal degeneration antisense oligonucleotides Stargardt disease inherited retinal diseases splicing modulation RNA therapy ABCA4 iPSC-derived photoreceptor precursor cells cyclic GMP apoptosis necrosis drug delivery systems translational medicine Usher syndrome Leber congenital amaurosis RPE65 nonprofit patient registry translational protein trafficking protein folding protein degradation chaperones chaperonins heat shock response unfolded protein response autophagy therapy IRD DNA therapies RNA therapies compound therapies clinical trials Retinitis Pigmentosa GTPase Regulator adeno-associated viral Retinitis Pigmentosa (RP) choroideremia REP1 inherited retinal disease treatment apical polarity crumbs complex fetal retina PAR complex retinal organoids retinogenesis gene augmentation adeno-associated virus (AAV) 3-03943-176-5 3-03943-177-3 Garanto, Alejandro edt Collin, Rob W.J. oth Garanto, Alejandro oth |
language |
English |
format |
eBook |
author2 |
Garanto, Alejandro Collin, Rob W.J. Garanto, Alejandro |
author_facet |
Garanto, Alejandro Collin, Rob W.J. Garanto, Alejandro |
author2_variant |
r w c rw rwc a g ag |
author2_role |
HerausgeberIn Sonstige Sonstige |
title |
Molecular Therapies for Inherited Retinal Diseases |
spellingShingle |
Molecular Therapies for Inherited Retinal Diseases |
title_full |
Molecular Therapies for Inherited Retinal Diseases |
title_fullStr |
Molecular Therapies for Inherited Retinal Diseases |
title_full_unstemmed |
Molecular Therapies for Inherited Retinal Diseases |
title_auth |
Molecular Therapies for Inherited Retinal Diseases |
title_new |
Molecular Therapies for Inherited Retinal Diseases |
title_sort |
molecular therapies for inherited retinal diseases |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2020 |
physical |
1 electronic resource (262 p.) |
isbn |
3-03943-176-5 3-03943-177-3 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT collinrobwj moleculartherapiesforinheritedretinaldiseases AT garantoalejandro moleculartherapiesforinheritedretinaldiseases |
status_str |
n |
ids_txt_mv |
(CKB)5400000000042749 (oapen)https://directory.doabooks.org/handle/20.500.12854/69174 (EXLCZ)995400000000042749 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Molecular Therapies for Inherited Retinal Diseases |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1796653160968749057 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05620nam-a2201321z--4500</leader><controlfield tag="001">993600242604498</controlfield><controlfield tag="005">20231214133600.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202105s2020 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000042749</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/69174</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000042749</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Collin, Rob W.J.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Molecular Therapies for Inherited Retinal Diseases</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (262 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Following the implementation of next-generation sequencing technologies (e.g., exome and genome sequencing) in molecular diagnostics, the majority of genetic defects underlying inherited retinal disease (IRD) can readily be identified. In parallel, opportunities to counteract the molecular consequences of these defects are rapidly emerging, providing hope for personalized medicine. ‘Classical’ gene augmentation therapy has been under study for several genetic subtypes of IRD and can be considered a safe and sometimes effective therapeutic strategy. The recent market approval of the first retinal gene augmentation therapy product (LuxturnaTM, for individuals with bi-allelic RPE65 mutations) by the FDA has not only demonstrated the potential of this specific approach, but also opened avenues for the development of other strategies. However, every gene—or even every mutation—may need a tailor-made therapeutic approach, in order to obtain the most efficacious strategy with minimal risks associated. In addition to gene augmentation therapy, other subtypes of molecular therapy are currently being designed and/or implemented, including splice modulation, DNA or RNA editing, optogenetics and pharmacological modulation. In addition, the development of proper delivery vectors has gained strong attention, and should not be overlooked when designing and testing a novel therapeutic approach. In this Special Issue, we aim to describe the current state of the art of molecular therapeutics for IRD, and discuss existing and novel therapeutic strategies, from idea to implementation, and from bench to bedside.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Research & information: general</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Biology, life sciences</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">induced pluripotent stem cell (iPSC)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clustered regularly interspaced short palindromic repeats (CRISPR)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">homology-directed repair (HDR)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Enhanced S-Cone Syndrome (ESCS)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NR2E3</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">AAV</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">retina</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gene therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dual AAV</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gold nanoparticles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA-wrapped gold nanoparticles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ARPE-19 cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">retinal pigment epithelium</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clathrin-coated vesicles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">endosomal trafficking</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">retinitis pigmentosa</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">autosomal dominant</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">G56R</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">putative dominant negative effect</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gapmer antisense oligonucleotides</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">allele-specific knockdown</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Leber congenital amaurosis and allied retinal ciliopathies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CEP290</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Flanders founder c.4723A &gt</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">T nonsense mutation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cilia elongation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">spontaneous nonsense correction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">AON-mediated exon skipping</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microRNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">photoreceptors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">rods</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cones</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bipolar cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Müller glia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">retinal inherited disorders</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">retinal degeneration</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antisense oligonucleotides</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Stargardt disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inherited retinal diseases</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">splicing modulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RNA therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ABCA4</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">iPSC-derived photoreceptor precursor cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cyclic GMP</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">apoptosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">necrosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug delivery systems</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">translational medicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Usher syndrome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Leber congenital amaurosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RPE65</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nonprofit</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">patient registry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">translational</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">protein trafficking</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">protein folding</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">protein degradation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chaperones</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chaperonins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">heat shock response</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">unfolded protein response</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">autophagy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">IRD</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA therapies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RNA therapies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">compound therapies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clinical trials</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Retinitis Pigmentosa GTPase Regulator</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adeno-associated viral</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Retinitis Pigmentosa (RP)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">choroideremia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">REP1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inherited retinal disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">apical polarity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">crumbs complex</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fetal retina</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PAR complex</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">retinal organoids</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">retinogenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gene augmentation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adeno-associated virus (AAV)</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-176-5</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-177-3</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Garanto, Alejandro</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Collin, Rob W.J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Garanto, Alejandro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:58:26 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5345733270004498&Force_direct=true</subfield><subfield code="Z">5345733270004498</subfield><subfield code="b">Available</subfield><subfield code="8">5345733270004498</subfield></datafield></record></collection> |